SCHEMBL30239137

SCHEMBL30239137

COC(=O)c1ccc2c(Cl)c3c(nc2c1)CCN(C(C)=O)C3

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMYD3 Q9H7B4 5/20 0.49
ALDH1A1 P00352 3/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
HTT P42858 1/20 0.49
MAPT P10636 5/20 0.48
TP53 P04637 5/20 0.48
KMT2A Q03164 2/20 0.48
POLB P06746 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MEN1 O00255 1/20 0.48
BLM P54132 1/20 0.48
MAPK1 P28482 2/20 0.47
LMNA P02545 1/20 0.47
PDE5A O76074 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31000795 1.00 SMYD3 (0.49) SMYD3ALDH1A1NPC1RAB9AHTT
SCHEMBL30239120 0.88 ALDH1A1 (0.52) SMYD3ALDH1A1NPC1RAB9AHTT
SCHEMBL24931211 0.82 NPC1 (0.49) SMYD3ALDH1A1NPC1RAB9AHTT
SCHEMBL30239625 0.82 NPC1 (0.49) SMYD3ALDH1A1NPC1RAB9AHTT
SCHEMBL16401275 0.79 BAZ2B (0.48) MAPTLMNAPDE5A
SCHEMBL16403812 0.78 PDE5A (0.63) MAPTTP53POLBSMN1; SMN2PDE5A
SCHEMBL17792391 0.77 PDE5A (0.58) MAPTPOLBPDE5A
SCHEMBL16410989 0.75 PDE5A (0.54) ALDH1A1MAPTKMT2ASMN1; SMN2MAPK1
SCHEMBL30239064 0.74 ALDH1A1 (0.51) SMYD3ALDH1A1NPC1RAB9AHTT
SCHEMBL24931199 0.74 ALDH1A1 (0.51) SMYD3ALDH1A1NPC1RAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376076-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) DANA-FARBER CANCER INSTITUTE, INC. 2024-11-14 US disclosed
CN-118401507-A Inhibitors targeting ubiquitin-specific protease 7 (USP 7) 丹娜法伯癌症研究院 2024-07-26 CN disclosed
EP-4373816-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) Dana-Farber Cancer Institute, Inc. (US) 2024-05-29 EP disclosed
WO-2023003973-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376076-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) USP7, USP47, USP2 SMYD3 2835/4885ALDH1A1 2692/4885NPC1 1511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.